title: [Beta-blockade with timolol after myocardial infarction (author's transl)].
abstract: In a recently published study, timolol lowered the overall mortality by 43% and the reinfarction rate by 37% during an average duration of treatment of 17 months after myocardial infarction. Although the timolol study is the best and most convincing of the post-infarction therapy studies yet presented, some important questions remain unanswered; in particular, the effect of other measures (eg the control of risk factors) is not clear. The future role of timolol will depend on further analysis of the study and on the definition of its significance as part of a comprehensive management plan of post-infarction patients.
mesh_terms: D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D006801:Humans; D009203:Myocardial Infarction / Q000188:drug therapy* / Q000401:mortality; D011412:Propanolamines / Q000627:therapeutic use*; D013999:Timolol / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D011412:Propanolamines; D013999:Timolol
vernacular_title: Beta-Blockade mit Timolol nach Myokardinfarkt.